Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 15, 2024

NOD-scid IL2Rγnull (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ)

RRID:BCBC_4142 Type: Organism

Proper Citation

RRID:BCBC_4142

Organism Information

URL:

Proper Citation: RRID:BCBC_4142

Species: Mus musculus

Phenotype: Diabetes mellitus

Catalog Number: 4142

Background: TM

Database: BCBC, Beta Cell Biology Consortium

Database Abbreviation: BCBC

Organism Name: NOD-scid IL2RÎ3null (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ)

Ratings and Alerts

No rating or validation information has been found for NOD-scid IL2Rγnull (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ).

No alerts have been found for NOD-scid IL2Rγnull (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ).

Data and Source Information

Source: Integrated Animals

Source Database: BCBC, Beta Cell Biology Consortium

Usage and Citation Metrics

We found 97 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Xia L, et al. (2024) Osimertinib Covalently Binds to CD34 and Eliminates Myeloid Leukemia Stem/Progenitor Cells. Cancer research, 84(3), 479.

Magnani CF, et al. (2023) Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells. Molecular therapy oncolytics, 30, 56.

Zhao M, et al. (2023) Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan. NPJ breast cancer, 9(1), 66.

Lupo KB, et al. (2023) TIGIT contributes to the regulation of 4-1BB and does not define NK cell dysfunction in glioblastoma. iScience, 26(12), 108353.

Huang D, et al. (2023) Sex- and Female Age-Dependent Differences in Gene Expression in Diffuse Large B-Cell Lymphoma-Possible Estrogen Effects. Cancers, 15(4).

Guo H, et al. (2023) DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs. Cell, 186(13), 2765.

Ricordel C, et al. (2023) Genomic characteristics and clinical significance of CD56+ circulating tumor cells in small cell lung cancer. Scientific reports, 13(1), 3626.

Lehmann J, et al. (2023) Escape from NK cell tumor surveillance by NGFR-induced lipid remodeling in melanoma. Science advances, 9(2), eadc8825.

Li S, et al. (2023) Remodeling Serine Synthesis and Metabolism via Nanoparticles (NPs)-Mediated CFL1 Silencing to Enhance the Sensitivity of Hepatocellular Carcinoma to Sorafenib. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 10(19), e2207118.

Sharma S, et al. (2023) Constitutive Interleukin-7 Cytokine Signaling Enhances the Persistence of Epstein-Barr Virus-Specific T-Cells. International journal of molecular sciences, 24(21).

Jones S, et al. (2023) Application of a 3D hydrogel-based model to replace use of animals for passaging patient-derived xenografts. In vitro models, 2(3-4), 99.

Atre T, et al. (2023) Age and ligand specificity influence the outcome of pathogen engagement on preleukemic and leukemic B-cell precursor populations. Blood advances, 7(22), 7087.

Gray E, et al. (2023) SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models. Journal for immunotherapy of cancer, 11(10).

Zhang X, et al. (2023) IDR-induced CAR condensation improves the cytotoxicity of CAR-Ts against low-antigen cancers. bioRxiv: the preprint server for biology.

Tian M, et al. (2023) Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma. Cell reports. Medicine, 4(10), 101212.

Fan H, et al. (2023) DNA damage induced by CDK4 and CDK6 blockade triggers anti-tumor immune responses through cGAS-STING pathway. Communications biology, 6(1), 1041.

Alsalloum A, et al. (2023) Exploring TCR-like CAR-Engineered Lymphocyte Cytotoxicity against MAGE-A4. International journal of molecular sciences, 24(20).

Singhal SK, et al. (2023) Schlafen 12 Slows TNBC Tumor Growth, Induces Luminal Markers, and Predicts Favorable Survival. Cancers, 15(2).

Fanlo L, et al. (2023) Neural crest-related NXPH1/?-NRXN signaling opposes neuroblastoma malignancy by inhibiting organotropic metastasis. Oncogene, 42(28), 2218.

Bell HL, et al. (2023) Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia. Cancer cell international, 23(1), 202.